OMCL Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of 0.11%. Omnicell, Inc.'s return on equity of 1.6% beat Astrana Health, Inc.'s return on equity of 1.85%.

Omnicell, Inc. has a consensus price target of $51.50, signalling upside risk potential of 13.01%. On the other hand Astrana Health, Inc. has an analysts' consensus of $37.6667 which suggests that it could grow by 56.88%. Given that Astrana Health, Inc. has higher upside potential than Omnicell, Inc., analysts believe Astrana Health, Inc. is more attractive than Omnicell, Inc..

Omnicell, Inc. has a beta of 0.831, which suggesting that the stock is 16.868% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

Omnicell, Inc. quarterly revenues are $310.6M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. Omnicell, Inc.'s net income of $5.5M is higher than Astrana Health, Inc.'s net income of $1.1M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 106.87x while Astrana Health, Inc.'s PE ratio is 128.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.80x versus 0.41x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of 9.58%. Omnicell, Inc.'s return on equity of 1.6% beat Cryo-Cell International, Inc.'s return on equity of --.

Omnicell, Inc. has a consensus price target of $51.50, signalling upside risk potential of 13.01%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 130.9%. Given that Cryo-Cell International, Inc. has higher upside potential than Omnicell, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Omnicell, Inc..

Omnicell, Inc. has a beta of 0.831, which suggesting that the stock is 16.868% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.21% to investors and pays a quarterly dividend of $0.15 per share. Omnicell, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Omnicell, Inc. quarterly revenues are $310.6M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Omnicell, Inc.'s net income of $5.5M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Omnicell, Inc.'s price-to-earnings ratio is 106.87x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.80x versus 0.91x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

10X Genomics, Inc. has a net margin of 1.76% compared to Omnicell, Inc.'s net margin of -18.44%. Omnicell, Inc.'s return on equity of 1.6% beat 10X Genomics, Inc.'s return on equity of -10.32%.

Omnicell, Inc. has a consensus price target of $51.50, signalling upside risk potential of 13.01%. On the other hand 10X Genomics, Inc. has an analysts' consensus of $17.36 which suggests that it could grow by 5.2%. Given that Omnicell, Inc. has higher upside potential than 10X Genomics, Inc., analysts believe Omnicell, Inc. is more attractive than 10X Genomics, Inc..

Omnicell, Inc. has a beta of 0.831, which suggesting that the stock is 16.868% less volatile than S&P 500. In comparison 10X Genomics, Inc. has a beta of 2.148, suggesting its more volatile than the S&P 500 by 114.813%.

Omnicell, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 10X Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omnicell, Inc. pays -- of its earnings as a dividend. 10X Genomics, Inc. pays out -- of its earnings as a dividend.

Omnicell, Inc. quarterly revenues are $310.6M, which are larger than 10X Genomics, Inc. quarterly revenues of $149M. Omnicell, Inc.'s net income of $5.5M is higher than 10X Genomics, Inc.'s net income of -$27.5M. Notably, Omnicell, Inc.'s price-to-earnings ratio is 106.87x while 10X Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omnicell, Inc. is 1.80x versus 3.18x for 10X Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.